SequelSEC

VERACYTE, INC. VCYT

Services-Medical Laboratories · CIK 0001384101 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$561.90M
Fiscal year ended 2026-06-30
Operating income
$105.77M
Fiscal year ended 2026-06-30
Free cash flow
$165.99M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.70BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$21.39Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income25.6×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue3.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Effective tax rate2.7%0th
FCF margin24.5%100th
Net margin12.8%95th
Gross margin70.1%92th
Operating margin11.2%90th
Current ratio8.15x80th
CapEx / revenue1.9%29th
R&D / revenue13.7%31th
Revenue YoY growth16.0%55th
SBC / revenue8.4%45th

VERACYTE, INC. (VCYT) reported revenue of $561.90M and net income of $114.48M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VERACYTE, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

VERACYTE, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$561.90M
Cost of revenueUnavailable
Gross profit$402.96M
Operating income$105.77M
Net income$114.48M
Research & development$93.37M
Weighted-average diluted sharesUnavailable
Pretax income$116.02M
Income tax expense$1.54M
Diluted EPSUnavailable
Selling, general & administrative$201.58M
General & administrative$95.77M
Selling & marketing$105.81M

Balance

VERACYTE, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$299.52M
Total assets$1.49B
Current assets$574.78M
Total liabilities$97.96M
Current liabilities$62.74M
Total equity incl. NCI$1.39B
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$54.18M
Goodwill$767.15M
Long-term debtUnavailable
Accounts payable$8.02M

Cash flow

VERACYTE, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$178.38M
Capital expenditures$12.39M
Investing cash flow-$98.67M
Financing cash flow$338.00K
Net change in cash$80.03M
Stock-based compensation$48.50M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$20.83M

Derived

VERACYTE, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$165.99M
Gross margin71.7%
Operating margin18.8%
FCF margin29.5%
SBC / revenue8.6%
Current ratio9.16x
Revenue YoY growth17.3%
Net margin20.4%
R&D / revenue16.6%
CapEx / revenue2.2%
Long-term debt / equityUnavailable
Effective tax rate1.3%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VCYT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ACON ADVB AMS BDSX BGLC BLLN CAI CDNA CELC CFOR CSTL DGX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.